EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Changing Management of Focal Cerebral Arteriopathy of Childhood From 2010 to 2022

Heather J Fullerton iD, Nancy K Hills iD, Hui Chen iD, Nomazulu Dlamini iD, Nicholas V Stence, Max Wintermark iD, VIPS II Investigators

Stroke · 2025

DOI: 10.1161/strokeaha.124.050550 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Stroke, 2025. Verfasst von Heather J Fullerton und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Neurology (H.J.F., N.K.H.), University of California San Francisco. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Cerebral Arterial Diseases, Ischemic Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The most common cause of arterial ischemic stroke in healthy children, focal cerebral arteriopathy (FCA), can progress rapidly over days with worsening brain injury. A 2017 retrospective Swiss study of corticosteroid treatment for FCA changed practice. To assess its impact, we compared the FCA cohorts from the 2 VIPS (Vascular Effects of Infection in Pediatric Stroke) prospective cohort studies. METHODS: The VIPS II study prospectively enrolled 205 children (29 days to 18 years) with arterial ischemic stroke at 22 centers, December 2016 to January 2022. The local team measured 12-month outcomes using the pediatric stroke outcome measure. A neuroradiologist and pediatric vascular neurologist independently reviewed all clinically obtained imaging and clinical data to classify the cause of arterial ischemic stroke. The neuroradiologist measured the FCA Severity Score on vascular imaging performed at any time poststroke. We compared the VIPS II FCA cohort to the previously published FCA cohort from VIPS I (2010–2014; 37 centers). RESULTS: Of 75 children with definite arteriopathy enrolled in VIPS II, 32 (43%) had FCA, compared with 41 of 127 (32%) of definite arteriopathy cases in VIPS I. The median age was 11.3 years (56% male) in VIPS I and 11.4 years (55%) in VIPS II. Treatment with intravenous corticosteroids increased from 2 of 41 (5%) of FCA patients in VIPS I to 18 of 32 (56%) in VIPS II. The VIPS II FCA cases were more severe at baseline (median FCA Severity Score 6 versus 4; P =0.006). There were no significant differences in either the change in FCA Severity Score (baseline to maximum) or the 12-month neurological outcomes. CONCLUSIONS: Treatment of FCA with corticosteroids increased dramatically between the VIPS I and VIPS II studies. VIPS II cases were more severe at baseline, but we observed no significant difference in disease progression or neurological outcomes. Given the low level of evidence supporting corticosteroid therapy, pediatric stroke centers should enroll FCA patients into ongoing FCA corticosteroid treatment trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT04873583 and NCT06040255.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Cortex HormonesCerebral Arterial DiseasesIschemic StrokeAdolescentChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleCohort StudiesDisease ManagementProspective StudiesRetrospective StudiesClinical Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

cerebrovascular disordersdisease progressionischemic strokeoutcome assessment, health carestroke

Substanzen

Adrenal Cortex Hormones

Autor:innen und Institutionen

  • Departments of Neurology (H.J.F., N.K.H.), University of California San Francisco.
  • Pediatrics (H.J.F.), University of California San Francisco.
  • Biostatistics and Epidemiology (N.K.H.), University of California San Francisco.
  • Department of Radiology, MD Anderson Cancer Center, Houston, TX (H.C., M.W.).
  • Department of Paediatrics, Division of Neurology, Hospital for Sick Children, Toronto, Canada (N.D.).
  • Department of Radiology, University of Colorado, Denver (N.V.S.).

ORCID-Profile: Heather J Fullerton, Nancy K Hills, Hui Chen, Nomazulu Dlamini, Max Wintermark

Förderung

  • NINDS NIH HHS

Zitieren

APA

Fullerton, H. J., Hills, N. K., Chen, H., Dlamini, N., Stence, N. V., Wintermark, M., & VIPS II Investigators (2025). Changing Management of Focal Cerebral Arteriopathy of Childhood From 2010 to 2022. Stroke. https://doi.org/10.1161/strokeaha.124.050550

Vancouver

Fullerton HJ, Hills NK, Chen H, Dlamini N, Stence NV, Wintermark M, et al. Changing Management of Focal Cerebral Arteriopathy of Childhood From 2010 to 2022. Stroke. 2025. doi:10.1161/strokeaha.124.050550

BibTeX
@article{Fullerton2025,
  author = {Fullerton, Heather J and Hills, Nancy K and Chen, Hui and Dlamini, Nomazulu and Stence, Nicholas V and Wintermark, Max and VIPS II Investigators, VIPS II Investigators},
  title = {Changing Management of Focal Cerebral Arteriopathy of Childhood From 2010 to 2022},
  journal = {Stroke},
  year = {2025},
  doi = {10.1161/strokeaha.124.050550}
}
Kostenlos starten →